Your browser doesn't support javascript.
loading
Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097.
Weisberg, Ellen; Halilovic, Ensar; Cooke, Vesselina G; Nonami, Atsushi; Ren, Tao; Sanda, Takaomi; Simkin, Irene; Yuan, Jing; Antonakos, Brandon; Barys, Louise; Ito, Moriko; Stone, Richard; Galinsky, Ilene; Cowens, Kristen; Nelson, Erik; Sattler, Martin; Jeay, Sebastien; Wuerthner, Jens U; McDonough, Sean M; Wiesmann, Marion; Griffin, James D.
Afiliação
  • Weisberg E; Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. ellen_weisberg@dfci.harvard.edu james_griffin@dfci.harvard.edu.
  • Halilovic E; Novartis Institutes of Biomedical Research, Cambridge, Massachusetts.
  • Cooke VG; Novartis Institutes of Biomedical Research, Cambridge, Massachusetts.
  • Nonami A; Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Ren T; National Screening Laboratory for the Regional Centers of Excellence in Biodefense and Emerging Infectious Diseases Research, Harvard Medical School, Boston, Massachusetts.
  • Sanda T; Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Simkin I; Molecular Genetics Core, Boston University School of Medicine, Boston, Massachusetts.
  • Yuan J; Novartis Institutes of Biomedical Research, Cambridge, Massachusetts.
  • Antonakos B; Novartis Institutes of Biomedical Research, Cambridge, Massachusetts.
  • Barys L; Novartis Institutes of Biomedical Research, Basel, Switzerland.
  • Ito M; Novartis Institutes of Biomedical Research, Basel, Switzerland.
  • Stone R; Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Galinsky I; Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Cowens K; Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Nelson E; Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Sattler M; Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Jeay S; Novartis Institutes of Biomedical Research, Basel, Switzerland.
  • Wuerthner JU; Novartis Institutes of Biomedical Research, Basel, Switzerland.
  • McDonough SM; Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Wiesmann M; Novartis Institutes of Biomedical Research, Basel, Switzerland.
  • Griffin JD; Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. ellen_weisberg@dfci.harvard.edu james_griffin@dfci.harvard.edu.
Mol Cancer Ther ; 14(10): 2249-59, 2015 Oct.
Article em En | MEDLINE | ID: mdl-26206331
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperazinas / Leucemia Mieloide Aguda / Proteína Supressora de Tumor p53 / Proteínas Proto-Oncogênicas c-mdm2 / Isoquinolinas / Antineoplásicos Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperazinas / Leucemia Mieloide Aguda / Proteína Supressora de Tumor p53 / Proteínas Proto-Oncogênicas c-mdm2 / Isoquinolinas / Antineoplásicos Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2015 Tipo de documento: Article